Subscribe
VBCC - Media Library - Interview with the Innovators
Ralph V. Boccia, MD, FACP
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Related Items
Challenges in Treating Multiple Myeloma and the Impact of New Oral Oncolytics
VBCC - September 2015, Vol 6, No 8 published on September 17, 2015 in Interview with the Innovators
Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach
VBCC - April 2015, Vol 6, No 3 published on April 22, 2015 in Interview with the Innovators
Unclear Diagnoses in Patients with Metastatic Disease
Ralph V. Boccia, MD, FACP
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
Clinical Validation of CancerTYPE ID
Ralph V. Boccia, MD, FACP
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
CancerTYPE ID in the Clinic
Ralph V. Boccia, MD, FACP
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
CancerTREATMENT NGS+ in the Clinic
Ralph V. Boccia, MD, FACP
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
Managing Costs in Oncology Care
Ralph V. Boccia, MD, FACP
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
When to Use Breast Cancer Index
Susan K. Boolbol, MD, Stephen C. Malamud, MD
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
Benefits of Breast Cancer Index
Susan K. Boolbol, MD, Stephen C. Malamud, MD
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
BCI Effects and Survivorship
Susan K. Boolbol, MD, Stephen C. Malamud, MD
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
Last modified: July 27, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology